• In April 2026, Pacira BioSciences filed a preliminary proxy urging shareholders to support its three board nominees over those put forward by DOMA Perpetual Capital Management, while also presenting new real-world data at a major managed care pharmacy meeting showing EXPAREL’s economic and opioid-sparing profile in outpatient hip and knee replacements.
• The combination of proxy contest developments and fresh health-economic evidence for EXPAREL’s use in high-volume joint procedures sharpens the focus on how Pacira’s governance and non-opioid portfolio positioning could influence its long-term outlook with payers and providers.
• We’ll now examine how the new real-world EXPAREL cost and opioid-use data may influence Pacira BioSciences’ broader investment narrative.

Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

Pacira BioSciences Investment Narrative Recap

To own Pacira, you really need to believe that EXPAREL and the broader non opioid portfolio can keep gaining traction with payers and outpatient surgeons, while governance stays stable enough to execute on that plan. The latest proxy fight and new real world EXPAREL data do not appear to change the near term focus on payer coverage and outpatient procedure volumes as key catalysts, nor do they materially alter the core risk of heavy reliance on a single flagship product.

The AMCP data on outpatient hip and knee replacements looks most relevant here, because it speaks directly to payer and provider value in high volume surgeries. Evidence that EXPAREL use is associated with lower or comparable total healthcare costs and reduced opioid utilization in certain populations could reinforce existing catalysts tied to CMS changes and non opioid adoption, while also highlighting the ongoing risk that pricing power could come under pressure as bundled payments and cost containment intensify.

Yet while this cost and opioid use story is encouraging, investors should also be aware that...

Pacira BioSciences' narrative projects $908.9 million revenue and $112.0 million earnings by 2028.

Uncover how Pacira BioSciences' forecasts yield a $29.00 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Pacira could lift revenue to about US$1.2 billion and earnings to about US$96.0 million, but this new EXPAREL data and renewed activism could either support that view or challenge it, depending on how you weigh pricing pressure and product concentration risk over time.

Explore 3 other fair value estimates on Pacira BioSciences - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pacira BioSciences research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Pacira BioSciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pacira BioSciences' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.